INS and Hyperglycemia: The underlying pathogenesis of COVID-19–related hyperglycemia can be described by the damage to pancreatic β-cells and decreased insulin sensitivity and altered insulin secretion due to the activation of the renin-angiotensin system (RAS) and the host’s inflammatory response to COVID-19.